# Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

> **NCT05132101** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 2758 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Patients who received Palbociclib as first line therapy in MBC setting

## Key facts

- **NCT ID:** NCT05132101
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-20
- **Primary completion:** 2022-03-14
- **Final completion:** 2022-03-14
- **Target enrollment:** 2758 (ACTUAL)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132101, "Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05132101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*